G protein-coupled receptor 35 (GPR35) has been characterized to be one of the genes that are up-regulated in human heart failure. Since mechanisms controlling GPR35 expression are not known, we investigated the regulation of GPR35 gene and protein expression in cardiac myocytes and in the mouse models of cardiac failure.
Introduction
G protein-coupled receptors (GPCRs) belong to one of the largest and most studied gene families in the genome 1 and constitute the largest family of receptors. G protein-coupled receptor 35 (GPR35) is a 309 amino acid seven-transmembrane domain receptor originally characterized as an orphan receptor. 2 Ligand screening studies have revealed that GPR35 can be activated by a tryptophan metabolite, kynurenic acid (KYNA), which is found in the plasma in nano to micromolar concentrations. 3 Recent results suggest that lysophosphatidic acids (LPAs), and especially 2-acyl LPAs, could also be endogenous ligands for GPR35 and activate the receptor at nanomolar concentrations. 4 In addition to the putative endogenous ligands, several synthetic GPR35 activators have been found. 5 -7 GPR35 activation triggers cellular responses in a cell type-specific manner. In dorsal root ganglion neurons, GPR35 is coupled with pertussis toxin (PTX)-sensitive G i protein. 8, 9 GPR35 overexpression and activation was shown to inhibit neuronal N-type calcium channels, and the repressor effect could be blocked by pre-treatment with PTX. 10 Recently, GPR35 activation has been connected to alternative b-arrestin-2 and Ga 13 pathways, and it was also shown that at least part of the GPR35 signalling involves PTX-sensitive ERK1/2 activation. 6, 11, 12 Several lines of evidence suggest that GPR35 may have a role in cardiac physiology and pathology. Knock-out mice lacking GPR35 expression have been reported to have increased systemic blood pressure, 13 but the mechanism is not known. In addition, high amounts of GPR35 were shown to be expressed in the wild-type mice hearts, and myocardial GPR35 gene expression was shown to be associated with human heart failure. 13 At the cellular level, adenoviral overexpression of GPR35 causes hypertrophic-like changes in the cell morphology and reduced cellular viability. 13 Interestingly, a genome-wide association study suggested that GPR35 single-nucleotide polymorphism was linked to coronary artery calcification and coronary artery disease. 14 Mutation was a risk factor and replicable predictor for the development of coronary atherosclerosis in studied individuals. These findings suggest that GPR35 has very likely a role also in the cardiovascular system. The function of GPR35 in cardiac muscle cells is still largely unclear, and even less is known about the regulation of GPR35 gene expression. Since hypoxia is involved in the majority of cardiac pathophysiological processes, we aimed to investigate whether GPR35 gene expression is regulated by oxygen and whether the expressional regulation is involved in cardiac pathologies.
Methods

Cell cultures
Neonatal mouse cardiomyocytes were isolated 1 -2 days after birth. Animals were sacrificed by decapitation, ventricles were excised and the cardiomyocytes were isolated and cultured as previously described. 15 The HL-1 cell line was maintained as described earlier. 16 To induce hypoxia, cardiomyocytes were cultured in a Biospherix C-Chamber (model C-274, Biospherix Ltd, USA) or in Invivo 2 400 hypoxia chamber (Ruskinn Technology Ltd, UK) as previously. 15 CD-1 mice from the Center for Experimental Animals at the University of Oulu were used. The experimental designs were approved by the Animal Use and Care Committee of the University of Oulu.
Transfection and reporter analysis
Cell transfections with pCMV-Flag-Inhibitory Per/Arnt/Sim domain protein (IPAS) and pFlag-hypoxia-inducible factor (HIF)-1a(1-390)-VP16 constructs and hypoxia or desferrioxamine (DFO) exposure were done as previously. 15 
Gene expression measurements
Q-PCR primers and probes for mouse GPR35 were designed to detect both reported splicing variants separately and together. Variants encode the same protein, but differ in the 5 ′ UTR regions, so that variant NM_022320.3 represents the longer transcript and NM_001104529.1 the shorter one.
GPR35 overexpression constructs
GPR35 overexpression plasmids were generous gifts from Mr Stephen R. Ikeda and have been described earlier.
10 GPR35-Venus protein localization and trafficking was determined by imaging with Olympus FV1000 and Zeiss LSM 780 laser-scanning confocal microscopes.
GPR35 promoter constructs
The GPR35 promoter was amplified from mouse heart genomic DNA. Oligonucleotide primers were designed on the basis of the longer GPR35 transcript variant 1 (NM_022320.3). The final product corresponded to the promoter region from 22435 to +192 bp relative to the transcription start site (TSS) (+1) on the mouse GPR35 promoter. Amplified product was inserted to pGL3-basic reporter plasmid (Promega, Madison, USA) to generate full-length GPR35-Luc plasmid construct. Promoter 5 ′ -end truncated constructs were generated by restriction and PCR deletion reactions. Nucleic acid sequences were qualified after each step by sequencing promoter fragments with the ABI PRISM 3100 sequencing system (Applied Biosystems, USA).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as previously described by Sahu et al. 17 with Hif-1a rabbit antiserum (ab2185 Abcam, UK) and normal rabbit serum (NRS). Hif-1a binding was examined with PCR primers specific for the GPR35 HIF-1 site or for the negative control area 1000 bp upstream from the site.
Immunofluorescence labelling and measurement of the cell sizes
Cells were fixed with 3% paraformaldehyde for 10 min in RT. Lifespan LS-A2 anti-GPR35-antibody (LifeSpan Biosciences, WA, USA) was used as a primary antibody. Secondary antibody was Alexa Fluor 488 chicken antirabbit (Molecular Probes, USA). Actin fibres were labelled with Phalloidin-TRITC (Sigma Aldrich, USA) and nuclei with DAPI (Molecular Probes, USA). Images were taken with a Olympus FV1000 confocal microscope (Olympus, Japan) and image analysis was done with the ImageJ software. Lifespan LS-A2 GPR35-antibody specificity was characterized and is shown in Supplementary material online, Figure S1 . Sizes of EGFP and GPR35 overexpressing cells were determined by ImageJ/Fiji softwares' Threshold and Analyse Particles-based functions.
Experimental animals
All animal procedures were approved by The National Animal Experiment Board of Finland and carried out in accordance with the guidelines of the directive 2010/63/EU of the European Parliament; 10 -15-week-old C57Bl male mice (Harlan Laboratories, Inc., Indianapolis, IN, USA) were used. The animals were kept in standard housing conditions in The National Laboratory Animal Center of The University of Eastern Finland. Diet and water were provided ad libitum.
Myocardial infarction and transversal aortic constriction
Myocardial infarction (MI) was done by permanently ligating the left anterior descending (LAD) coronary artery as previously described. 18 Mice were anaesthetized with isoflurane (induction: 4.5% isoflurane, 450 mL air, maintenance: 2.0% isoflurane, 200 mL air, Baxter International, Inc., Deerfield, IL, USA). Sham-operated animals went through the same operation, but the suture was not ligated. Analgesic (carprofen 5 mg/kg, Rimadyl, Pfizer, Inc., New York, NY, USA; bubrenorfin 0.05-1 mg/kg, Temgesic, RB Pharmaceuticals Limited, Berkshire, UK) was given post-operatively and on the following 3 days. Animals were sacrificed 1 and 4 days after the operation with CO 2 or by cervical dislocation. Transversal aortic constriction (TAC) was done as described earlier.
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Medetomidine (1 mg/kg, s.c., Domitor w , Pfizer, Inc.,) and ketamine (75 mg/kg, s.c., Ketalar w , Pfizer, Inc.,) were used as anaesthetics and postoperative analgesic (carprofen 5 mg/kg, Rimadyl, Pfizer, Inc., , bubrenorfin 0.05-1 mg/kg, Temgesic, RB Pharmaceuticals Limited, Berkshire, UK) and anti-sedative (atipamezole hydrochloride 0.1 -1 mg/kg, Antisedan, Orion Oyj, Espoo, Finland) were given. Animals were sacrificed 2 and 4 weeks after the operation with CO 2 or by cervical dislocation.
Echocardiography
Echocardiographic measurements were performed before the surgical operations and on the day of sacrifice with the Vevo770 Ultrasound System (VisualSonics, Inc., Toronto, Ontario, Canada) as previously described. 20 For TAC-operated animals, ejection fraction (EF) and left ventricle diastolic wall thickness were determined from parasternal short-axis M-Mode measurements. EF was calculated by the Vevo770 software by using the Teicholz formula. For LAD-operated animals, EF and endocardial area in diastole were determined from the parasternal long-axis B-Mode V-P. Ronkainen et al.
with Simpson's method and calculated by the Vevo770 software. Different analyses were used due to the different type of the defect (global pressure load vs. local infarction).
Immunohistochemistry
Tissue samples were fixed with 4% paraformaldehyde in 7.5% sucrose for 4 h, automatically processed and embedded in paraffin. GPR35 (LS-A2, dilution 1:100, LifeSpan Biosciences, WA, USA), Hif-1a (ab114977, dilution 1:250, Abcam, Cambridge, UK), and capillary endothelium [Biotinylated Griffonia (Bandeiraea) Simplicifolia Lectin I, dilution 1:100, Vector Laboratories, Burlingame, CA, USA] were immunostained from 5 mm thick sections by using the avidin -biotin -HRP system.
Western blot
About 40 mg of protein from lysed ventricular tissue was used for western blot analysis on 10% SDS -polyacrylamide gel. After transferring the protein to nitrocellulose membrane, the membrane was incubated with GPR35 (sc-79511, Santa Cruz) or GAPDH (2118, Cell Signaling Technology) primary antibody. After incubation with horseradish peroxidase-linked secondary antibody, blots were visualized with ECL Plus Detection Kit (GE Healthcare) using a Typhoon 9400 scanner (GE Healthcare).
Capillary assessment
The mean capillary area and the capillary/mm 2 ratio were analysed from five microscopic fields of endothelium-stained sections at ×400 magnification within each animal.
Analysis of the microarray data
Microarray data were obtained from NCBI's GEO DataSets database (http ://www.ncbi.nlm.nih.gov/gds/). Raw data in Affymetrix CEL-files (from GEO data series GSE36630 and GSE18801) were analysed in R software environment for statistical computing using the Bioconductor packages.
Statistics
The values are presented as means + SEM or SD. Statistical significance was evaluated using an unpaired Student's t-tests for comparisons of two mean values. Multiple comparisons involving more than two groups were performed using ANOVA followed by Bonferroni post hoc tests. P-values of ,0.05 were considered statistically significant.
Results
GPR35 expression is induced by hypoxia and HIF-1
To study whether GPR35 expression is sensitive to hypoxia, we exposed different types of cultured cardiomyocytes to hypoxia. Hypoxia increased the expression of GPR35 mRNA in neonatal cardiac and HL-1 cells. In neonatal cardiomyocytes, the GPR35 mRNA levels were elevated significantly in 12 h (P , 0.001, n ¼ 8), increasing further up to 48 h (P , 0.001, n ¼ 8) ( Figure 1A ). At the same time, the expression of a known hypoxia-regulated marker gene, EGL nine homolog 3 (PHD3), showed similar induction (24 h, P , 0.001, n ¼ 8) ( Figure 1A ). The GPR35 hypoxia response was also similar in embryonic cardiomyocytes (E12.5) (P , 0.001, n ¼ 6), indicating that the regulation is not developmentally regulated (see Supplementary material online, Figure S2 ). When cardiomyocytes were exposed to varying levels of O 2 (from 0.5 to 20%), GPR35 expression was shown to be more sensitive to hypoxia than PHD3, half-maximal activation of GPR35 was 2.9% O 2 , whereas the PHD3 expression from the same samples showed half-maximal activation at 1.8% O 2 ( Figure 1B) . The GPR35 gene produces two different isoforms through alternative splicing, 21 but the functional differences of the isoforms are still not clear. 21 Cardiac myocytes express both GPR35a and GPR35b splicing variants at equivalent amounts, and the responses of both variants to hypoxia were similar (see Supplementary material online, Figure S3 ). Further GPR35 gene expression measurements were therefore performed by measuring the NM_022320.3 transcripts. Next, we wanted to study whether hypoxic induction of GPR35 gene expression is translated into an increase in the amount of cell surface GPR35 receptors. Receptors were detected as 0.2 mm 2 spots on plasma membranes of paraformaldehyde-fixed, un-permeabilized cardiomyocytes ( Figure 1C) . Calculations from confocal microscope z-stack maximum intensity projection images of GPR35-antibody-stained cells showed that hypoxia (1% O 2 , 48 h) increased the number of plasma membrane immunoreactive GPR35 spots from a normoxic average of 142 to hypoxic 196 spots/cell (P , 0.01, n ¼ 22/21) ( Figure 1C ). Receptor coverage area/cell was increased from 34 to 44 mm 2 /cell (P , 0.01) without a change in the cellular surface area (determined from combined DIC-images, not shown) (P . 0.05, n ¼ 22/21) resulting in an increase in the receptor-covered plasma membrane area from 4.2 to 5.2% (P , 0.05, n ¼ 22/21). These findings indicate that an increased amount of GPR35 gene expression results in an increased amount of GPR35 protein at the cell membrane.
Since a vast majority of transcriptional effects of hypoxia is mediated by HIF-transcription factors, we next exposed cardiomyocytes to prolyl hydroxylase inhibitor DFO, a chemical activator of HIF. DFO activated HIF-1-dependent transcription in normoxia and increased GPR35 expression in neonatal mouse ventricular and HL-1 cardiomyocytes (P , 0.001, n ¼ 6) ( Figure 1D) . A similar response was seen in PHD3 expression (P , 0.001, n ¼ 6). To further characterize the role of HIF-1 in the regulation of GPR35 expression, we overexpressed constitutively active, normoxia-stabile HIF-1 [HIF-1a(1-390)-VP16], and HIF-1-inhibiting IPAS (pCMV-Flag-IPAS) in HL-1 cells, as previously described. 15 The expression of HIF-1a(1-390)-VP16 increased GPR35
gene expression in normoxia (P , 0.01, n ¼ 6) ( Figure 1D ). Supporting the role of HIF in this process, the hypoxic induction of GPR35 was abolished (P , 0.001, n ¼ 6) in cells expressing the specific HIF inhibitor IPAS ( Figure 1D ). Together, these overexpression studies emphasize that GPR35 transcription is likely to be regulated by HIF-1.
HIF-1 activates GPR35 expression through a specific HRE-site at GPR35 promoter
The mouse GPR35 promoter contains one putative HIF-binding 5 ′ -ACGTG-3 ′ site located at 2372 bp 5 ′ -direction from the TSS. To characterize the function of the putative hypoxia response element (HRE), we assembled a GPR35 promoter-luciferase reporter construct containing the GPR35 promoter fragment from 22435 to +192 bp relative to TSS (Figure 2A) . HL-1 cells were transiently transfected with the reporter construct and luciferase activity was measured after various HIF-1 activity-modulating stimuli. Construct activity followed the characteristics of the endogenous gene, as hypoxia (P , 0.001, n ¼ 4), DFO (P , 0.001, n ¼ 4), and HIF-1a(1-390)-VP16 (P , 0.001, n ¼ 4) all increased luciferase expression. In addition, HIF-1 inhibition by IPAS reduced the promoter activity in hypoxia (P , 0.001, n ¼ 4). Promoter 5 ′ -end deletions showed that HIF-1-dependent activity still prevailed in a shorter promoter construct (2881 to +192 bp) containing the putative HRE, but was lost in a 2361 to + 192 bp promoter that lacks the proposed HRE (Figure 2A) . When the 5 ′ -ACGTG-3 ′ sequence of the hypoxia-responsive construct (2881 to +192) was mutated to
Hypoxia-dependent regulation of GPR35 5 ′ -CATGT-3 ′ , the HIF-and hypoxia-dependent induction of the GPR35 promoter was abolished (Figure 2A) . Hypoxia, DFO, and HIF-1a(1 -390)-VP16 were not able to induce (P . 0.05, n ¼ 4 in all groups) the luciferase expression of the mutated promoter construct ( Figure 2A) . To confirm these findings on the level of endogenous HIF-1 protein and endogenous GPR35 gene promoter, HIF-1 binding was verified by chromatin immunoprecipitation using HIF-1-specific antibody (ChIP). Quantitative PCR-based ChIP analyses showed that the binding of the HIF-1 to GPR35 promoter HRE increases in hypoxic cells (P , 0.01, n ¼ 3) ( Figure 2B ). Amplification of a negative non-specific promoter region at 5 ′ -direction upwards from the HRE did not show increment in HIF-1 binding during hypoxia. These findings confirm a pre-requisite role of the functional 2372 bp HRE to the HIF-1-mediated activation of the GPR35 gene in hypoxic cardiac myocytes.
GPR35 ligand induces receptor internalization in cardiac myocytes
Most activated GPCRs are desensitized and internalized after activation. GPR35 internalization is induced by various ligands including KYNA, 2-acyl LPA, pamoic acid, and zaprinast. 6, 8 Since it is not known how GPR35 activation is manifested in cardiac myocytes, we overexpressed GPR35a(S294)-Venus 10 in neonatal mouse cardiomyocytes and HL-1 cells and followed the changes in the cellular location of GPR35 with time-lapse live cell confocal microscopy in response to GPR35 agonist Zaprinast 5 ( Figure 3) . Overexpressed GPR35 was mainly located on the plasma membranes of the myocytes. However, application of Zaprinast (10 mM) induced GPR35 internalization and subcellular accumulation in 60 min. In neonatal cardiomyocytes and HL-1 cells, the GPR35s were translocated to the peri-nuclear area, corresponding to the location sarco/endoplasmic reticulum in cardiomyocytes. 22 This suggests that the overexpressed receptor was functional and active in cardiac myocytes and responded to the ligand stimulation. It is, therefore, likely that GPR35 activation evokes similar intracellular signalling pathways in cardiac myocytes as reported earlier in other cell types.
6,8
Overexpression of GPR35 modulates cardiomyocyte morphology
Overexpression of GPR35 results in a tonic activation of GPR35 10 and the activity is probably further augmented by endogenous GPR35 ligands, such as LPAs, 4 which are present in serum 23 and actively secreted to the culture medium. 24 Endogenous ligands of GPR35, such as LPAs, mediate diverse effects on proliferation, cell motility, and migration through Rho-mediated signalling pathways 24 and promote distinct morphological changes including cytoskeletal rearrangements, appearance of retraction fibres, and membrane ruffling. 25 In line with these results, the expression of GPR35 in neonatal mouse cardiomyocytes resulted in pronounced cellular ruffling-type morphology and formation of retraction fibres ( Figure 4A ). These changes were associated with a disruption of the cellular actin fibre network and loss of sarcomeric-like structures typical for cardiac myocytes ( Figure 4B ). Control cells Neonatal ventricular cardiomyocytes were cultured in either normoxia or hypoxia. After immunoprecipitation with HIF-1a antibody (HIF-1) or normal rabbit serum (NRS), the captured chromatin was used as a template in qPCR with primers specific for the HIF-1 site region (including HRE) and a negative site control region. HIF-1 binding to HRE increases in hypoxia, whereas the negative site 1 kb in the 5 ′ -direction from the HRE does not show increased HIF-binding in hypoxia.
Hypoxia-dependent regulation of GPR35 expressing EGFP retained their morphology without a disruption of the actin filament network and their cellular shape remained similar to the un-transfected myocytes. These morphological changes suggest that GPR35 triggers pathways that mitigate the phenotypes of cardiac myocytes. Overexpression of GPR35 did not change the size of cultured neonatal cells nor did it induce gene expression of hypertrophic markers in HL-1 cardiac cells (see Supplementary material online, Figure S4 ) suggesting that GPR35 is not causing hypertrophy in these cells.
GPR35 expression is an early marker of progressive remodelling in mice
Because GPR35 expression was previously implicated in human heart failure, 13 we next studied whether GPR35 expression is changed in mouse models of acute MI and pathological hypertrophy. In rodents subjected to ligation of the LAD artery, hypoxia-sensitive gene expression is usually associated with an acute lack of oxygen following the operation. 15 In line with this, expression of hypoxia-sensitive genes PHD3 and GPR35 was increased (P , 0.05, n ≥ 4) in left ventricle of mouse 1 day after LAD ligation, whereas their expression did not differ from that of SHAM-operated mice 4 days after ligation ( Figure 5A ). In both time points, the hearts had clear signs of cardiac dysfunction measured by decreased EF (P , 0.001, n ≥ 4) ( Figure 5B) . Also, an increased endocardial area showed progressive impairment of cardiac performance (P , 0.05, n ≥ 4) ( Figure 5B ). As assumed, ANP, a commonly known hypertrophic marker gene, was not changed in a model of acute myocardial hypoxia ( Figure 5A ). According to immunohistochemical staining, GPR35
is expressed in SHAM-and LAD-operated mice and it is located on the membranes and in the cytosol ( Figure 5C ). Interestingly, GPR35 also appears in the surface of vacuolar structures in the cytosol. Immunohistochemical stainings of GPR35 and HIF-1 from the same areas confirm that hypoxia is prevailing in the areas where GPR35 expression is seen (see Supplementary material online, Figure S5A-D) . The amount of GPR35 protein, indicated by immunohistochemical staining, was the highest at Day 1 after the LAD operation ( Figure 5C ), which is in line with the corresponding mRNA levels ( Figure 5A ). Four days after the ligation, GPR35 Hypoxia-dependent regulation of GPR35
protein expression returned to the same level with SHAM-operated hearts (see Supplementary material online, Figure S6A ), following the changes in GPR35 gene expression that also returned to the level of that in SHAM-operated animals ( Figure 5A ). HIF-1 activation is also involved in pressure overload-induced cardiac remodelling, 26 although the degree of hypoxia is likely to be moderate compared with deep hypoxia induced by acute infarction. To test if GPR35 is activated in pressure-overloaded hearts, we measured GPR35 transcripts from mice subjected to TAC. The levels of GPR35 and ANP expression were increased at 2 weeks (P , 0.05, n≥7) and remained elevated also at 4 weeks (P , 0.001, n ≥ 7) after TAC operation, whereas hypoxia-sensitive PHD3 was not changed at any time point ( Figure 5D ). Interestingly, expressions of both ANP and GPR35 were associated with the compensatory phase of hypertrophy at 2-week time point, when echocardiographically assessed EF and left ventricle inner diameter (LVID) of the hearts were normal ( Figure 5E ). Four weeks after the operation, the mice had developed cardiac failure with decreased EF (P , 0.001, n ≥ 4) and increased LVID (P , 0.01, n ≥ 4) ( Figure 5E ). Pressure overload triggered also physiological angiogenesis seen as an increased mean capillary area in the myocardium (see Supplementary material online, Figure S7A ) and slight increase in the amount of capillaries per myocyte at 2 and 4 weeks after TAC operation (see Supplementary material online, Figure S7B ). Immunohistochemical staining showed that GPR35 was expressed more at 2 and 4 weeks after TAC operation compared with SHAM-operated hearts ( Figure 5F ). GPR35 was located throughout the myocyte cytosols in majority of the cells. Nuclear translocation of HIF-1 coincides with GPR35 protein expression in the histological sections from the same myocardial area (see Supplementary material online, Figure S5E -H). Four weeks after the TAC operation GPR35 protein expression was similarly induced as the gene expression in the same time point (see Supplementary material online, Figure S6B ). Analysis of public microarray data shows that the GPR35 gene is not induced in pregnancy or exercise-induced hypertrophy (see Supplementary material online, Table S1 ). Collectively, these data indicate that GPR35 expression responds to hypoxia following cardiac infarction, but also precedes the development of cardiac failure in pressure-overloaded mouse heart.
Discussion
We found that GPR35 is expressed in mouse cardiomyocytes throughout development as well as in HL-1 cell line. In all of these models, GPR35 gene expression was increased in hypoxia upon activation of HIF-1. We also demonstrated that a specific HRE is pre-requisite for the hypoxic induction of the GPR35 gene. In cardiomyocytes, ligand binding to GPR35 induced receptor internalization and overexpression of GPR35 caused morphological changes in cardiomyocytes. Our results also show that GPR35 expression is a marker for cardiac hypoxia in acute MI and an early marker of heart failure in a mouse model of progressive cardiac hypertrophy.
Expression of GPR35 is regulated by hypoxia and HIF-1
So far, there are no published studies about the regulation of GPR35 gene expression. In this study, GPR35 was characterized as a novel hypoxia-sensitive gene having a functional HRE at 2372 bp 5 ′ -direction from the TSS linking GPR35 expression to activation of HIF-1. Our findings also indicate that increased mRNA expression is translated into increased GPR35 protein on the plasma membrane. GPR35 expression was rather sensitive to reduction of oxygen since half-maximal induction of the expression was already reached at 2.9% O 2 , which is higher than the threshold for PHD3 (1.8% O 2 ), a prototypical hypoxia marker gene. Earlier reports have shown that HIF-1 DNA-binding activity increases exponentially from 5% O 2 to 0.5% O 2 , with half-maximal response being between 1.5 and 2% O 2 . 27 Among the hypoxia-sensitive genes, GPR35 seems to be relatively sensitive to hypoxia, which may have interesting physiological implications. For example, GPR35 expression was increased in heart failure at the same time when prototypical hypoxiasensitive cardiac genes were unaltered. 13 This result could be due to the fact that GPR35 expression is activated in vivo already at a relatively modest oxygen deprivation, and could therefore participate in physiological regulation of the heart in situations where the heart is facing mild hypoxia.
Effects of GPR35 in cardiac myocytes
In this study, GPR35 reported to launch receptor-mediated stress fibre formation with the regulation of the actin cytoskeleton. 29, 30 In addition, GPR35 activation has also been linked to of b-arrestin signalling 6 also known to induce membrane ruffling and retraction fibre formation. 31 
GPR35 expression in cardiac hypertrophy and failure
In a previous gene array analysis of human heart failure, GPR35 was identified to be among the top 12 genes whose expression correlates with the severity of the heart failure. 13 GPR35s are expressed in the hearts of mouse and humans and adenoviral overexpression of GPR35 causes hypertrophic-like morphology changes and reduced cellular viability in cardiac myocytes. 13 Interestingly, knock-out mice lacking GPR35 expression were reported to have increased systemic blood pressure, 13 but the heart phenotype of GPR35-KO mice has not been further characterized. The expressions of hypoxia-and HIF-1-dependent genes, such as apelin and adrenomedullin, are usually associated with early phases of cardiac infarction, but are not elevated at later phases when infarction proceeds to cardiac failure. 15 In infarcted mouse's heart, GPR35 expression behaved like a typical hypoxia response gene, showing clear increase in the acute phase of the infarction with unaltered expression at later phases. In addition to the absolute lack of oxygen during cardiac infarction, the myocardium may also face the relative lack of oxygen, when oxygen delivery cannot meet the demands of increase in oxygen consumption due to increased work load, as during pressure-overloaded heart. While hypoxia-sensitive gene expression is not considered to be a prototypical marker of cardiac pressure overload, HIF-1-dependent transcription has been shown to have a central role in the load-induced cardiac remodelling 26 with activation of HIF-1 and up-regulation of some of HIF-1 target genes, such as VEGF. 32 According to our results, in pressure-overloaded mouse's heart the expression of HIF-1-sensitive GPR35 is increased in both compensatory V-P. Ronkainen et al. and decompensatory phase of the hypertrophy. While we cannot fully exclude the possibility that other factors than HIF-1 induce GPR35 expression in the overloaded heart, it is highly likely that the hypoxia is one of the major factors inducing GPR35 expression. Owing to the fact that GPR35 expression is more sensitive to hypoxia compared with majority of HIF-1 target genes, we propose that GPR35 expression could be triggered by the moderate hypoxia of the core of the ventricle wall at the time of increased work load. Collectively, our results identify GPR35 as a novel HIF-1 target gene in the heart in vivo and in vitro. In cardiac myocytes, GPR35 forms functional receptors and is internalized upon ligand binding. Overexpression of GPR35 induces distinct changes in the morphology of the cardiac myocytes. In vivo the expression of GPR35 is induced by moderate hypoxia during increased cardiac workload as well as during deep hypoxia induced by cardiac infarction. According to our results, GPR35 expression could be used as a novel predictive marker of the development of cardiac failure of different aetiologies.
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